News

UCB will adopt Veeva ePRO and Veeva eConsent.

New capability added to VIDA Intelligence Platform will streamline quality-controlled data curation.

In this Q&A, John Kastelein, MD, founder and chief scientific officer, NewAmsterdam Pharma, discusses the challenges and opportunities within the cardiovascular field, exploring the current landscape for lipid-lowering therapies and the unique potential advantages of CETP inhibitors.

Senior leaders gather to share insights on the increased investment in real-world data to boost the quality and efficiency of drug development—as the industry begins to more widely embrace evidence of proven outcomes in aiding approaches in clinical trial design, patient engagement, regulatory decision-making, and other areas.

Latest enhancements will optimize Omnichannel capabilities for ROI reporting.

Examining the two areas of weakness cited in FDA draft guidance.

The latest people and business news from the past month, all in one place.

Stakeholders must alter their mindsets when it comes to early-phase design and interpreting regulatory guidance for CGT trials.

EMA opens formal consultation on the pros and cons of basing pivotal evidence for new drug submissions on SAT data.

Worldwide will serve as Every Cure’s clinical trial and drug development partner.

Increased data output from the use of devices can accelerate trials for this therapeutic area in need of new therapies.

Parexel identified five roadblocks to participation and eight solutions for designing more equitable clinical trials for transgender and nonbinary patients.

Tool targets advanced drug monitoring and safety—and enables access to real-world data.

Clinvest Research specializes in chronic diseases and conditions including migraine, arthritis, and diabetes.

New technology aims to streamline cancer treatment process.

Acquisition of two previously merged companies bolsters ACRS’s patient-centric solutions for clinical development.

French and Spanish CROs combine on expertise to address cross-country clinical trials.

Profiles are based on data from more than 60 million patients, with aim to enable adoption of digital twins and improve patient centricity in drug development.

Recommendations apply to where some or all the trial-related activities occur at locations other than traditional clinical trial sites.

Clariness tasked with gathering data on digital device usage behaviors, app and notification preferences, and previous trial experiences.

Flatiron Health’s scalable EHR-to-EDC technology to enable efficient site data transfer for faster access to cleaner data with less burden.

New patient-facing digital platform provides access to trial-related information such as financial views, submission of receipts for reimbursement, and more.

Webinar Date/Time: Thursday, May 25th, 2023 at 11am EDT | 8am PDT | 4pm BST | 5pm CEST

Partnership Network gives sponsors and CROs the opportunity to share data and solutions.

January 2023 guidance from FDA on dosages in oncology provides further context on expectations with Project Optimus.

Survey shows comfort with e-signatures is on the rise, yet healthcare consent still lags.

Acquired site has specialized in neurodegenerative diseases for over 25 years.

Company opens research site in Littleton, CO.